Klin Padiatr 2023; 235(03): 191
DOI: 10.1055/s-0043-1768498
Abstracts

Expression of retinoic acid receptor gamma is modulated by miR-30a

A Barrett
1   Institute of Cancer Research
,
J-Y Shi
2   Shanghai Institute of Hematology
,
L Howell
1   Institute of Cancer Research
,
Y Sbirkov
3   Medical University of Plovdiv
,
G Brown
4   University of Birmingham
,
A Zelent
5   Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences
,
K Petrie
6   University of Sunderland, School of Medicine, City Campus, Chester Road, Tyne and Wear, UK.
› Institutsangaben
 
 

    All-trans-retinoic acid (ATRA) plays critical regulatory roles in normal haematopoiesis and the pathogenesis of adult and pediatric acute myeloid leukemia (AML). While ATRA can inhibit growth and stimulates myeloid differentiation via RARα, it is equally potent in causing expansion of haematopoietic stem cells via RARγ. RARG mRNA is expressed in AML patients and normal stem/progenitor cells but not in more mature myeloid cells. Changes in RARγ expression are paralleled by a reciprocal change in expression of RARG 3’-targeting miRNAs (mIR-24, mIR-30a, mIR-331). RARγ protein and RARG mRNA are also expressed in cell lines derived from primary AML samples but not in ATRA-responsive AML cell lines. Lastly, expression of mIR-30a in TEX cells promotes differentiation and inhibits proliferation. Our results suggest that miRNA-mediated down-regulation of RARγ expression in the myeloid lineage switches ATRA responsiveness from RARγ-mediated pro-proliferation to RARα-mediated pro-differentiation and that the combinatorial use of RARα and RARγ selective agonists and antagonists, respectively, could be effective in retinoid-based differentiation therapy of AML.


    #

    Publikationsverlauf

    Artikel online veröffentlicht:
    12. Mai 2023

    © 2023. Thieme. All rights reserved.

    Georg Thieme Verlag
    Rüdigerstraße 14, 70469 Stuttgart, Germany